Soterenol
 | |
| Clinical data | |
|---|---|
| Other names | MJ-1992 |
| Drug class | Adrenergic; Bronchodilator; Antiasthmatic; β-Adrenergic receptor agonist |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H20N2O4S |
| Molar mass | 288.36 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Soterenol (INN), also known as soterenol hydrochloride (USAN; developmental code name MJ-1992) in the case of the hydrochloride salt, is a drug of the phenethylamine family described as an adrenergic, bronchodilator, and antiasthmatic which was never marketed.[1][2][3] It is an analogue of salbutamol and acts as a β-adrenergic receptor agonist.[3][2] The drug was first developed in 1964[3] and was first described in the literature by 1967.[1]
References
[edit]- ^ a b Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 1107. ISBN 978-1-4757-2085-3. Retrieved 17 October 2024.
- ^ a b Morton I, Morton I, Hall J (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 260. ISBN 978-0-7514-0499-9. Retrieved 17 October 2024.
- ^ a b c Sneader W (2005). Drug Discovery: A History. Wiley. p. 191. ISBN 978-0-471-89979-2. Retrieved 17 October 2024.